Viking Therapeutics Refreshes Its Pipeline: Could Oral GLP‑1s Be the Next Big Thing?

Viking Therapeutics (NASDAQ: VKTX) has just released an update that many in the biotech community are chewing over. After a quiet few months, the company laid out a roadmap that threads together a handful of late‑stage programs, a handful of early‑stage assets, and, most importantly, a renewed focus on oral glucagon‑like peptide‑1 (GLP‑1) therapies.

Why the buzz? The market for GLP‑1 drugs—think Ozempic and Wegovy—has exploded, but it’s still dominated by injectables. Patients, doctors, and payers alike are eyeing the next wave: a pill you can swallow instead of a needle you have to lift. Viking believes it can be part of that wave, and the new update tries to prove it.

First up, the company highlighted its lead candidate, VKT‑124. This molecule is a small‑molecule agonist of the GLP‑1 receptor designed to be taken orally once daily. According to the latest pre‑clinical data, VKT‑124 shows comparable glucose‑lowering efficacy to current injectable GLP‑1s, while also delivering modest weight loss in rodent models. The data aren’t perfect—some variability in the pharmacokinetic profile was noted—but the team says it’s a manageable issue.

On the clinical side, Viking disclosed that the Phase 1b study in healthy volunteers wrapped up earlier this year. Safety looks clean, with only mild GI complaints that are typical of the class. More importantly, the study demonstrated dose‑dependent exposure and a half‑life that supports once‑daily dosing. The company is now preparing a Phase 2b trial in patients with type 2 diabetes, slated to start in Q4 2026.

Beyond VKT‑124, the update introduced a second oral candidate, VKT‑330, which targets the GLP‑1/GLP‑2 dual receptor. Early animal work suggests a synergistic effect on both glycemic control and gut‑derived hormone release, a combination that could set Viking apart from pure GLP‑1 players. The program is still in the pre‑clinical stage, but the executives say it will move into IND‑enabling studies within the next 12‑18 months.

Viking didn’t forget about its broader pipeline. The company reaffirmed its partnership with Cellenix for the development of a novel GIP/GLP‑1 combo, a strategy that’s been gaining traction after the success of tirzepatide. While that collaboration is still early‑stage, the firm believes it could feed into a “next‑generation” oral formulation down the line.

Financially, the update was a mixed bag. Viking reported a modest cash burn of $45 million for the last quarter, offset by a $30 million infusion from a strategic partnership with a Japanese pharma. The balance sheet still shows enough runway to fund the Phase 2b trial of VKT‑124, but the CFO warned that additional capital may be needed to advance the dual‑receptor program.

Analysts are cautiously optimistic. The consensus price target rose 12 % after the update, reflecting the market’s appetite for oral GLP‑1s. Yet, skeptics point out that Viking is competing against giants like Novo Nordisk and Eli Lilly, which have deep pipelines and massive commercial machines.

All things considered, Viking’s pipeline refresh paints a picture of a company betting hard on the next frontier of diabetes care—oral peptides. Whether that gamble pays off will hinge on the outcomes of the upcoming Phase 2b trial and the ability to secure more funding without diluting existing shareholders too much.

Investors should keep an eye on the data read‑outs slated for early 2027 and any partnership announcements that could accelerate the development timeline. Until then, the story remains a work in progress, with a fair share of scientific intrigue and financial risk intertwined.